HER2-POSITIVE EARLY BREAST CANCER
Clinical trials for HER2-POSITIVE EARLY BREAST CANCER explained in plain language.
Never miss a new study
Get alerted when new HER2-POSITIVE EARLY BREAST CANCER trials appear
Sign up with your email to follow new studies for HER2-POSITIVE EARLY BREAST CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New targeted drug challenges standard chemo in breast cancer trial
Disease control OngoingThis study is comparing two different treatment strategies for patients with early-stage, HER2-positive breast cancer before they have surgery. It aims to see if a newer, targeted drug called trastuzumab-deruxtecan (T-DXd) works better and is easier to tolerate than the current s…
Matched conditions: HER2-POSITIVE EARLY BREAST CANCER
Phase: PHASE2 • Sponsor: West German Study Group • Aim: Disease control
Last updated Mar 30, 2026 14:35 UTC
-
New drug combo aims to wipe out breast cancer before surgery
Disease control OngoingThis study is testing whether a newer targeted drug, either alone or in sequence with standard chemotherapy, works better than current standard chemotherapy when given before surgery for high-risk, early-stage HER2-positive breast cancer. It aims to see if more patients can achie…
Matched conditions: HER2-POSITIVE EARLY BREAST CANCER
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Mar 30, 2026 14:31 UTC